HALEOS LABS LIMITED Share Price & Stock Analysis

HALEOS LABS LIMITED (NSE: HALEOSLABS, BSE: 540679) is a Hyderabad, Telangana-based company in the Pharmaceuticals industry. With a market capitalisation of ₹423 Cr, it ranks #2,107 by market cap among the 6,197 Indian listed companies on FinBizNet, and #29 of 63 in Pharmaceuticals. At ₹1,588.90 (as of 16 Nov 2026), the share price is 10.4% below its 52-week high of ₹1,774.00 and 45.6% above its 52-week low of ₹1,091.10. The share price is up 38.2% over one year and up 7.8% over three months.

Key Metrics

Current Price₹1,588.90
Market Cap₹423 Cr
NSE SymbolHALEOSLABS
BSE Code540679
SectorHealth Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals
Sub-IndustryBiotechnology and Life Sciences > Pharmaceuticals
P/E Ratio27.9
Return on Equity8.06%
Return on Assets4.45%
52-Week Range₹1,091.10 – ₹1,774.00
1-Year Price Change+38.2%
3-Month Price Change+7.8%
Beta (1Y)0.34
Dividend Yield0.09%
HeadquartersHyderabad, Telangana
Websitehaleoslabs.com

Latest Quarterly Results — Q2 FY27

Revenue₹91 Cr
Net Profit₹2 Cr
Net Margin1.9%
EPS (Basic)₹10.77
Basisconsolidated

Figures in ₹ crore, parsed from the company's exchange filing (XBRL).

HALEOS LABS LIMITED Quarterly Revenue and Profit Trend

HALEOS LABS LIMITED reported revenue of ₹91 Cr in Q2 FY27, up 12.3% from ₹81 Cr in Q2 FY26 and up 25.3% from ₹73 Cr in Q1 FY27. It posted a net profit of ₹2 Cr for the quarter, against a net profit of ₹6 Cr in Q2 FY26 (down 72.6%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹73 Cr (Q1 FY27) to ₹95 Cr (Q3 FY26). The company was profitable in each of these 7 quarters.

QuarterRevenueNet ProfitNet Margin
Q2 FY27₹91 Cr₹2 Cr1.9%
Q1 FY27₹73 Cr₹2 Cr2.5%
Q4 FY26₹75 Cr₹0 Cr0.5%
Q3 FY26₹95 Cr₹7 Cr7.0%
Q2 FY26₹81 Cr₹6 Cr7.9%
Q1 FY26₹83 Cr₹4 Cr5.3%
Q4 FY25₹89 Cr₹3 Cr3.9%

Consolidated figures (₹ crore, XBRL filings).

Shareholding and Delivery

Promoters held 72.11% of HALEOS LABS LIMITED's shares as of Sept 2026, against 71.41% in Sept 2025 (+0.70 percentage points). Delivery averaged 78.8% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).

About HALEOS LABS LIMITED

Haleos Labs Limited engages in the manufacturing of active pharmaceutical ingredients (API) and intermediates in India. The company offers API and intermediates in areas, such as anti-ulcer, anti-migraine, anti-hypertensive, erectile dysfunction, anti-cancer, antifungal, anti-obesity, anti-emetic, anti-depressant, anti-worm, anti-infective, anti-gout, anti-convulsant, antiviral, and anesthesia, as well as antihistamine, diuretics, hair loss, and ophthalmic API products. It also exports its products. The company was formerly known as SMS Lifesciences India Limited and changed its name to Haleos Labs Limited in August 2025. Haleos Labs Limited was founded in 1990 and is based in Hyderabad, India.

Products and Services

1. Pharmaceutical-This segment researches, develops, manufactures, buys, imports, sells, and exports active pharmaceutical ingredients and its intermediates. 2. NA-NA 3. NA-NA 4. NA-NA

Business Segments

1. Manufacturing of Active Pharmaceutical Ingredients and Their Intermediates-100%

HALEOS LABS LIMITED vs Peers — Pharmaceuticals

CompanyMarket CapP/EROELatest Qtr Revenue1Y Change
Abbott India Ltd.₹56,531 Cr36.334.46%₹1,814 Cr-8.1%
Emcure Pharmaceuticals Ltd₹42,344 Cr47.919.57%₹2,820 Cr+73.3%
Ajanta Pharma Limited₹41,474 Cr39.425.39%₹1,794 Cr+27.8%
Piramal Pharma Ltd₹32,600 Crn/m-4.00%₹2,617 Cr+22.8%
RUBICON RESEARCH LIMITED₹28,526 Cr112.319.14%₹576 Cr+162.7%
Caplin Point Laboratories Ltdte₹18,155 Cr28.319.94%₹630 Cr+23.6%
Pfizer Ltd.₹17,811 Cr24.517.16%₹727 Cr-24.2%
Eris Lifesciences Ltd₹17,691 Cr28.318.07%₹892 Cr-17.5%
HALEOS LABS LIMITED₹423 Cr27.98.06%₹91 Cr+38.2%

Listed by market capitalisation. Ratios are shown for context only.

Frequently Asked Questions

What is the current share price of HALEOS LABS LIMITED?

HALEOS LABS LIMITED is trading at ₹1,588.90, with a market capitalisation of ₹423 Cr.

Which sector does HALEOS LABS LIMITED belong to?

HALEOS LABS LIMITED operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).

What are the key financial ratios of HALEOS LABS LIMITED?

HALEOS LABS LIMITED has a P/E of 27.9 and a return on equity of 8.06%.

What is the stock symbol of HALEOS LABS LIMITED?

HALEOS LABS LIMITED is listed on the NSE under the symbol HALEOSLABS and on the BSE under the scrip code 540679.

How has HALEOS LABS LIMITED's share price moved over the past year?

HALEOS LABS LIMITED's share price is up 38.2% over one year and up 7.8% over three months. Its 52-week range is ₹1,091.10 to ₹1,774.00.

What were HALEOS LABS LIMITED's latest quarterly results?

In Q2 FY27, HALEOS LABS LIMITED reported revenue of ₹91 Cr and net profit of ₹2 Cr, with basic EPS of ₹10.77 (consolidated, parsed from the company's exchange filing).

How have HALEOS LABS LIMITED's revenue and profit changed over the past year?

HALEOS LABS LIMITED reported revenue of ₹91 Cr in Q2 FY27, up 12.3% from ₹81 Cr in Q2 FY26 and up 25.3% from ₹73 Cr in Q1 FY27.

What is the promoter holding in HALEOS LABS LIMITED?

Promoters held 72.11% of HALEOS LABS LIMITED's shares as of Sept 2026, against 71.41% in Sept 2025 (+0.70 percentage points).

More on FinBizNet

Data as of 16 Nov 2026. Descriptive market data only — not investment advice.